Please assess the completion status of the following clinical trial:

Trial Title: Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of chronic obstructive pulmonary disease.~2. Relatively stable airway obstruction with post FEV1\< 80% predicted normal and post FEV1/FVC \<70%.~3. Male or female patients, 40 years of age or older.~4. Smoking history of more than 10 pack years.~Exclusion criteria:~1. Significant disease other than COPD~2. Clinically relevant abnormal lab values.~3. History of asthma.~4. Diagnosis of thyrotoxicosis~5. Diagnosis of paroxysmal tachycardia~6. History of myocardial infarction within 1 year of screening visit~7. Unstable or life-threatening cardiac arrhythmia.~8. Hospitalization for heart failure within the past year.~9. Known active tuberculosis.~10. Malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years~11. History of life-threatening pulmonary obstruction.~12. History of cystic fibrosis.~13. Clinically evident bronchiectasis.~14. History of significant alcohol or drug abuse.~15. Thoracotomy with pulmonary resection~16. Oral ß-adrenergics.~17. Oral corticosteroid medication at unstable doses~18. Regular use of daytime oxygen therapy for more than one hour per day~19. Pulmonary rehabilitation program in the six weeks prior to the screening visit~20. Investigational drug within one month or six half lives (whichever is greater) prior to screening visit~21. Known hypersensitivity to ß-adrenergic drugs, anticholinergics, BAC, EDTA~22. Pregnant or nursing women.~23. Women of childbearing potential not using a highly effective method of birth control~24. Patients who are unable to comply with pulmonary medication restrictions

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tiotropium+olodaterol low dose FDC (Type: EXPERIMENTAL): Once daily 2 puffs solution for inhalation Respimat
- tiotropium+olodaterol high dose FDC (Type: EXPERIMENTAL): Once daily 2 puffs solution for inhalation Respimat
- olodaterol (Type: ACTIVE_COMPARATOR): Once daily 2 puffs solution for inhalation Respimat
- tiotropium low dose (Type: ACTIVE_COMPARATOR): Once daily 2 puffs solution for inhalation Respimat
- tiotropium high dose (Type: ACTIVE_COMPARATOR): Once daily 2 puffs solution for inhalation Respimat

Based on this trial design, predict the completion outcome and termination type (if applicable).